1. Recognizing and Staging the Severity of NASH: What Tools Do We Have?

2. This program will include a discussion of off-label and investigational devices, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. What Is NASH?

4. Prevalence of NAFLD Growing in Parallel With Obesity and Metabolic Syndrome

5. Prevalence of NASH

6. Prevalence of NASH (cont)

7. Assessing Patients After NAFLD Diagnosis Factors to Identify When Considering Liver Biopsy

8. Initial Patient Assessment for Liver Biopsy

9. Biochemical Markers in NAFLD

10. Noninvasive Imaging Vibration-Controlled Transient Elastography

11. VCTE and AST/ALT Ratio

12. Noninvasive Imaging Interpretation VCTE, CAP, and ALT/AST

13. Who Is Not a Candidate for Liver Biopsy?

14. Review of Biomarkers for NAFLD/NASH

15. Future of Imaging for Patients With NAFLD MR

16. MRE

17. MRI-PDFF

18. Multiparametric MR

19. Next Steps: Imaging or Biopsy?

20. Key Takeaways

21. Key Takeaways (cont)

22. Abbreviations

23. Abbreviations (cont)